Immunovant
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The compa...
Latest News
5 days ago · zacks.com
Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 30.5% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
5 days ago · seekingalpha.com
Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline MomentumRoivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in rheumatoid arthritis, but regulatory and translational hurdles remain for broader adoption. Priovant's LISRAYA launches in dermatomyositis, with promising Phase 3 data in non-infectious uveitis, while Pulmovant's mosliciguat demonstrates best-in-class Phase 2 results in PH-ILD.
5 days ago · zacks.com
Immunovant (IMVT) Upgraded to Buy: Here's What You Should KnowImmunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
7 days ago · seekingalpha.com
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call TranscriptImmunovant, Inc. ( IMVT ) Q2 2027 Earnings Call November 9, 2026 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.
8 days ago · benzinga.com
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis StudyImmunovant (NASDAQ:IMVT) announced on Monday positive efficacy results from a clinical trial evaluating IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA).
8 days ago · marketbeat.com
What Immunovant (IMVT) Said on Its Q2 Earnings CallRoivant reported $31 million in net revenue from the initial launch of LISRAYA and highlighted new rheumatoid arthritis data for IMVT-1402 during its fiscal second-quarter earnings call. CEO Matt Gline cautioned that the LISRAYA results covered only about five weeks on the market and included a boost from pharmacy inventory.
8 days ago · globenewswire.com
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA) In exploratory analyses, ACR50 and ACR70 response rates for patients who remained on IMVT-1402 600 mg in Period 2 continued to increase, reaching 80.0% ACR50 and 52.5% ACR70 at Week 28 FDA discussions planned for later this year to determine the path forward regarding the registrational program for IMVT-1402 in D2T RA In light of the evolving Sjögren's disease (SjD) landscape and recent data in the field, we expect it is unlikely that we will advance IMVT-1402 further in SjD beyond the ongoing, fully enrolled Phase 2 trial All other clinical development timelines remain on track Roivant will host a live conference call and webcast at 8:00 a.m.
8 days ago · globenewswire.com
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business UpdateLISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA); FDA discussions planned for later this year to determine the path forward regarding the registrational program for IMVT-1402 in D2T RA Brepocitinib met the primary and all key secondary endpoints in the Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis (NIU); sNDA submission for NIU expected in the first half of calendar year 2027 Mosliciguat demonstrated positive topline data in the Phase 2 PHocus study in pulmonary hypertension associated with interstitial lung disease (PH-ILD); Phase 3 PHrontier study initiated In light of the evolving Sjögren's disease (SjD) landscape and recent data in the field, we expect it is unlikely that we will advance IMVT-1402 further in SjD beyond the ongoing, fully enrolled Phase 2 trial Roivant reported consolidated cash, cash equivalents and marketable securities of $4.2 billion as of September 30, 2026, including the cash payment received from Moderna in July, supporting cash runway into profitability Roivant will host a live conference call and webcast at 8:00 a.m.
27 days ago · globenewswire.com
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.
1 month ago · gurufocus.com
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC,
Analyst Summary
Add to Watchlist
Select watchlists to add or remove IMVT